Glucotrack (GCTK) risk factors, FY2024 10-K

Risks Related to our Business and Industry

1. 01We have a history of operating losses, and there is no assurance that we will generate material revenues or become profitable in the near future
2. 02As we continue to evolve from a company primarily involved in development to a company also involved in commercialization, we may encounter difficulties in managing our growth and expanding our operations successfully
3. 03We may have future capital needs and may not be able to obtain additional financing on acceptable terms
4. 04Raising additional capital may cause dilution to our existing stockholders and investors, restrict our operations, or require us to relinquish rights to our products and/or product candidates on unfavorable terms to us
5. 05Economic crises and market instability may materially and adversely affect the demand for our products, as well as our ability to obtain credit or secure funds through sales of our stock, which may materially and adversely affect our business, financial condition and ability to fund our operations
6. 06Glucotrack CBGM is not approved for sale in the United States or other jurisdictions
7. 07We are highly dependent on the success of our product candidate, Glucotrack CBGM, and cannot give any assurance that it will receive regulatory approval or clearance or be successfully commercialized
8. 08If our competitors develop and market products that are more effective, safer or less expensive than Glucotrack CBGM or our future product candidates, if any, our commercial opportunities will be adversely affected
9. 09We do not know whether our future clinical trials will begin on time, or at all, and whether ongoing and/or future clinical trials will be completed on schedule, or at all
10. 10The regulatory approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of Glucotrack CBGM or our future product candidates, if any
11. 11Failure to recruit and enroll patients for clinical trials may cause the development of our product candidates to be delayed
12. 12The terms of clearances or approvals and ongoing regulation of our products may limit how we manufacture and market our product candidates, which could materially impair our ability to generate anticipated revenues
13. 13Even if we receive regulatory clearance or approval to market Glucotrack CBGM or our future product candidates, if any, the market may not be receptive to our products
14. 14If the Glucotrack CBGM or our future product candidates, if any, fail to achieve market acceptance, we may not be able to generate significant revenue or achieve or sustain profitability
15. 15We may not obtain insurance coverage to adequately cover all significant risk exposures
16. 16If product liability lawsuits are brought against us, we may incur substantial liabilities
17. 17If we fail to attract and retain key management and scientific personnel, we may be unable to successfully develop or commercialize Glucotrack CBGM or our future product candidates, if any
18. 18We do not own or operate manufacturing facilities for clinical or commercial production of Glucotrack CBGM, other than a prototype lab. We have no experience in medical device manufacturing and lack the resources and the capability to manufacture the Glucotrack CBGM on a commercial scale
19. 19Independent clinical investigators and contract research organizations that we may engage to conduct our clinical trials may not be diligent, careful or timely
20. 20Our business may become subject to economic, political, regulatory and other risks associated with international operations, which could harm our business
21. 21The funding that we received through the Israeli Innovation Authority (“IIA”) for research and development activities restricts our ability to manufacture products or to transfer technology outside of Israel

Risks Related to Owning our Common Stock

1. 22We have never declared or paid any cash dividends on our Common Stock and do not anticipate paying any dividends on our Common Stock in the foreseeable future
2. 23In order to remain listed on Nasdaq, we must satisfy minimum financial and other continued listing requirements and standards, including those regarding director independence and independent committee requirements, minimum stockholders’ equity, minimum share price, and certain corporate governance requirements
3. 24There can be no assurance that we will be able to continue to maintain compliance with Nasdaq’s continued listing requirements, the Bid Price Rule, or other Nasdaq listing requirements. If we are not able to comply with applicable listing standards, our shares of Common Stock will be subject to delisting
4. 25We had identified a material weakness in our internal control over financial reporting, and we may not be able to successfully implement remedial measures
5. 26The market price of our Common Stock has been volatile and may continue to be volatile due to numerous circumstances beyond our control, and stockholders could lose all or part of their investment

Risks Related to Intellectual Property

1. 27If we are unable to obtain and enforce patent protection for our products, our business could be materially harmed
2. 28If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected
3. 29Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties
4. 30If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our product development and commercialization efforts
5. 31Security threats to our information technology infrastructure could expose us to liability and damage our reputation and business
6. 32If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and product could be significantly diminished
7. 33We may be subject to claims that our employees or consultants have wrongfully used or disclosed alleged trade secrets